

# Jeannette Lechner-Scott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4239378/publications.pdf>

Version: 2024-02-01

191  
papers

10,388  
citations

61945

43  
h-index

37183

96  
g-index

197  
all docs

197  
docs citations

197  
times ranked

13399  
citing authors

#	ARTICLE	IF	CITATIONS
1	The emerging role of artificial intelligence in multiple sclerosis imaging. Multiple Sclerosis Journal, 2022, 28, 849-858.	1.4	30
2	Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. journal of applied laboratory medicine, The, 2022, 7, 12-25.	0.6	7
3	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	1.8	5
4	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
5	CD4 <sup>+</sup> T-cell DNA methylation changes during pregnancy significantly correlate with disease-associated methylation changes in autoimmune diseases. Epigenetics, 2022, 17, 1040-1055.	1.3	4
6	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103385.	0.9	8
7	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.. Multiple Sclerosis and Related Disorders, 2022, 58, 103393.	0.9	3
8	Quantified hemodynamic parameters of the venous system in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2022, 57, 103477.	0.9	1
9	Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS. Neuroradiology Journal, 2022, 35, 592-599.	0.6	4
10	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	0.9	11
11	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	1.1	8
12	Reduced cognitive function contributes to economic burden of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 60, 103707.	0.9	8
13	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	1.4	2
14	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	1.7	3
15	Capturing SNP Association across the NK Receptor and HLA Gene Regions in Multiple Sclerosis by Targeted Penalised Regression Models. Genes, 2022, 13, 87.	1.0	1
16	High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. Multiple Sclerosis and Related Disorders, 2022, 61, 103816.	0.9	0
17	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	1.7	1
18	Prediction of Conversion from CIS to Clinically Definite Multiple Sclerosis Using Convolutional Neural Networks. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. <i>Multiple Sclerosis Journal</i> , 2021, 27, 465-474.	1.4	23
20	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
21	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.	1.4	7
22	Do people with multiple sclerosis receive appropriate support from the National Disability Insurance Scheme matching their level of disability? A description of disease "burden and societal cost in people with multiple sclerosis in Australia"™ (BAC-MS). <i>Australian Health Review</i> , 2021, 45, 745-752.	0.5	4
23	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
24	Air pollution and multiple sclerosis risk. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102797.	0.9	3
25	Biochemical Correlations with Fatigue in Multiple Sclerosis Detected by MR 2D Localized Correlated Spectroscopy. <i>Journal of Neuroimaging</i> , 2021, 31, 508-516.	1.0	2
26	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	41
27	B cell therapy and the use of RNA-based COVID-19 vaccines. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102887.	0.9	5
28	Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue. <i>European Journal of Radiology</i> , 2021, 137, 109610.	1.2	20
29	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102931.	0.9	2
30	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.5	15
31	Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103087.	0.9	8
32	004"…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
33	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103155.	0.9	12
34	The effectiveness of natalizumab vs fingolimod"…A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
35	011"…Worsening longitudinal reaction time trajectories using the MSReactor computerised battery predicts confirmed EDSS progression. , 2021, , .		0
36	008"…Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. , 2021, , .		1

#	ARTICLE	IF	CITATIONS
37	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	2.6	21
38	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
39	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e2020-e2031.	1.5	7
40	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 722237.	1.1	8
41	Possible Markers of Venous Sinus Pressure Elevation in Multiple Sclerosis: Correlations with Gender and Disease Progression. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103207.	0.9	7
42	Does the venous pressure theory of multiple sclerosis pathophysiology deserve a second chance?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103262.	0.9	3
43	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
44	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). <i>JMIR Research Protocols</i> , 2021, 10, e24969.	0.5	4
45	Response to treatment in NMOSD: the Australasian experience. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 58, 103408.	0.9	0
46	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426.	0.9	0
47	Developing a clinical“environmental”genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. <i>Brain Communications</i> , 2021, 3, fcab288.	1.5	7
48	Epigenome-wide association studies: current knowledge, strategies and recommendations. <i>Clinical Epigenetics</i> , 2021, 13, 214.	1.8	62
49	A pharmacogenetic study implicates NINJ2 in the response to Interferon- $\beta$ in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1074-1082.	1.4	5
50	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
51	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101486.	0.9	11
52	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
53	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2020, 77, 1496.	4.5	21
54	“Rocking the boat”with a new drug for neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102458.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Spiral MRSI and tissue segmentation of normal-appearing white matter and white matter lesions in relapsing remitting multiple sclerosis patients†. <i>Magnetic Resonance Imaging</i> , 2020, 74, 21-30.	1.0	7
56	Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102446.	0.9	8
57	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
58	The Incidence of Transverse Sinus Stenosis in Multiple Sclerosis: Further Evidence of Pulse Wave Encephalopathy. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102524.	0.9	12
59	Is multiple sclerosis a risk factor for infections?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102184.	0.9	2
60	Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102259.	0.9	8
61	Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes. <i>Clinical and Translational Medicine</i> , 2020, 10, 74-90.	1.7	7
62	The COVID-19 pandemic and the use of MS disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 102073.	0.9	153
63	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102212.	0.9	1
64	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. <i>Frontiers in Neurology</i> , 2020, 11, 537.	1.1	27
65	The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , 2020, 267, 1431-1443.	1.8	17
66	Ageing and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101953.	0.9	1
67	Comparison of BICAMS and ARCS for assessment of cognition in multiple sclerosis and predictive value of employment status. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102037.	0.9	7
68	Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients. <i>Scientific Reports</i> , 2020, 10, 22217.	1.6	9
69	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. <i>Neurology: Clinical Practice</i> , 2020, 10, 510-519.	0.8	17
70	Automatic and Robust Segmentation of Multiple Sclerosis Lesions with Convolutional Neural Networks. <i>Computers, Materials and Continua</i> , 2020, 66, 977-991.	1.5	12
71	Dare we mention the C-word?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102340.	0.9	0
72	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, A1-A2.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Multiple sclerosis and migration revisited. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, A1-A2.	0.9	3
74	Silent symptoms of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101453.	0.9	2
75	One size doesn't fit all. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, A1-A2.	0.9	0
76	Three suggestions to decrease the financial burden of MS treatments. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, A1.	0.9	0
77	Evaluation of MS related central fatigue using MR neuroimaging methods: Scoping review. <i>Journal of the Neurological Sciences</i> , 2019, 400, 52-71.	0.3	54
78	Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, A1-A2.	0.9	0
79	Multiple Sclerosis and Vitamin D "Caviar or a Dog's Dinner?". <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, A1-A2.	0.9	3
80	Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. <i>European Journal of Neurology</i> , 2019, 26, 1137.	1.7	33
81	131â€¦CLADIN: CLADribine and INnate immune responses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A42.3-A42.	0.9	0
82	134â€¦Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A43.3-A43.	0.9	0
83	002â€¦Therapeutic lag in relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A1.2-A1.	0.9	1
84	Grassroot efforts towards diversity in MS care and research: Win-win for patients and science. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, A1-A2.	0.9	0
85	2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641987708.	1.5	8
86	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
87	Diurnal variability of cerebral metabolites in healthy human brain with 2D localized correlation spectroscopy (2D Lâ€¦COSY). <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 592-601.	1.9	10
88	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35
89	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
90	Should our treatment target in MS include the intrathecal plasma cell response?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, A1-A2.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1800-1808.	1.4	7
92	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
93	Letter to the editor: blood processing and sample storage have negligible effects on methylation. <i>Clinical Epigenetics</i> , 2018, 10, 22.	1.8	14
94	Reliability of neurometabolite detection with two-dimensional localized correlation spectroscopy at 3T. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1559-1569.	1.9	4
95	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37
96	Cladribine versus fingolimod, natalizumab and interferon $\beta$ for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	1.4	36
97	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 127-137.	0.9	422
98	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	1.4	11
99	Automatic Prediction of the Conversion of Clinically Isolated Syndrome to Multiple Sclerosis Using Deep Learning. , 2018, , .		2
100	Can a stress management programme reduce stress and improve quality of life in people diagnosed with multiple sclerosis?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731881317.	0.5	6
101	Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. <i>Scientific Reports</i> , 2018, 8, 17418.	1.6	42
102	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	1.4	8
103	Diurnal stability and long-term repeatability of neurometabolites using single voxel 1H magnetic resonance spectroscopy. <i>European Journal of Radiology</i> , 2018, 108, 107-113.	1.2	9
104	Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients. <i>PLoS ONE</i> , 2018, 13, e0206511.	1.1	37
105	068â€“Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A28.1-A28.	0.9	2
106	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	0.9	17
107	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.3	22
108	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	4.5	20

#	ARTICLE	IF	CITATIONS
109	Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis. <i>BMC Medical Genomics</i> , 2018, 11, 48.	0.7	12
110	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. <i>Frontiers in Neurology</i> , 2018, 9, 16.	1.1	30
111	DNA methylation changes in CD4 <sup>+</sup> T cells isolated from multiple sclerosis patients on dimethyl fumarate. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731878782.	0.5	17
112	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. <i>Frontiers in Neurology</i> , 2018, 9, 418.	1.1	8
113	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318.	0.9	28
114	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
115	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
116	Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. <i>Journal of Biomedical Science</i> , 2017, 24, 17.	2.6	24
117	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
118	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
119	EBV and MS: Major cause, minor contribution or red-herring?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 16, 24-30.	0.9	43
120	Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638.	0.9	108
121	Anxiety Levels Are Independently Associated With Cognitive Performance in an Australian Multiple Sclerosis Patient Cohort. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 128-134.	0.9	21
122	Favourable Outcome in a 33-Year-Old Female with Acute Haemorrhagic Leukoencephalitis. <i>Case Reports in Neurology</i> , 2017, 9, 106-113.	0.3	11
123	Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1479-1487.	1.4	30
124	Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1063-1071.	1.4	45
125	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
126	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94



#	ARTICLE	IF	CITATIONS
127	Comparison of the sagittal sinus cross-sectional area between patients with multiple sclerosis, hydrocephalus, intracranial hypertension and spontaneous intracranial hypotension: a surrogate marker of venous transmural pressure?. <i>Fluids and Barriers of the CNS</i> , 2017, 14, 18.	2.4	16
128	Differential methylation at MHC in CD4+ T cells is associated with multiple sclerosis independently of HLA-DRB1. <i>Clinical Epigenetics</i> , 2017, 9, 71.	1.8	63
129	Anxiety, depression and fatigue at 5-year review following CNS demyelination. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 403-413.	1.0	47
130	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
131	Erythrocytes in multiple sclerosis – forgotten contributors to the pathophysiology?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731664998.	0.5	10
132	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 729-736.	1.7	21
133	Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. <i>Clinical Epigenetics</i> , 2016, 8, 87.	1.8	43
134	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
135	Comparative efficacy of first-line natalizumab vs IFN- $\beta$ or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	0.8	33
136	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. <i>Multiple Sclerosis Journal</i> , 2016, 22, 944-954.	1.4	21
137	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	0.9	76
138	A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?. <i>Fluids and Barriers of the CNS</i> , 2016, 13, 18.	2.4	36
139	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
140	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1349-1358.	1.4	54
141	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
142	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 373-387.	1.7	57
143	Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients. <i>Clinical Epigenetics</i> , 2015, 7, 118.	1.8	85
144	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	0.5	5

#	ARTICLE	IF	CITATIONS
145	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	3.1	19
146	A new era in the treatment of multiple sclerosis. <i>Medical Journal of Australia</i> , 2015, 203, 139-141.	0.8	10
147	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
148	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54
149	NLRP3 inflammasome is associated with the response to IFN-Î² in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	3.7	93
150	On the origin of Neurostatus. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 182-185.	0.9	62
151	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	1.7	43
152	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989.	1.7	32
153	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100
154	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5644-5654.	1.4	53
155	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
156	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
157	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	1.1	122
158	Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 489-491.	1.4	3
159	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	1.4	73
160	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	1.4	148
161	Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. <i>Multiple Sclerosis Journal</i> , 2014, 20, 675-685.	1.4	23
162	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.5	138

#	ARTICLE	IF	CITATIONS
163	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1835-1846.	0.8	15
164	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1847-1856.	0.8	22
165	Methylation differences at the <i>HLA-DRB1</i> locus in CD4+ T-Cells are associated with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1033-1041.	1.4	120
166	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	2.8	67
167	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1857-1865.	0.8	19
168	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	9.4	1,213
169	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	3.7	140
170	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308.	1.0	10
171	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	1.1	26
172	Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes. <i>Human Molecular Genetics</i> , 2013, 22, 2283-2292.	1.4	20
173	Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1268-1274.	1.4	10
174	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. <i>PLoS ONE</i> , 2013, 8, e59694.	1.1	38
175	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	1.4	56
176	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	0.9	37
177	Potential association of vitamin D receptor polymorphism<i>Taq1</i>with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 16-22.	1.4	55
178	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.3	35
179	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
180	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	1.1	166

#	ARTICLE	IF	CITATIONS
181	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
182	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 239, 101-104.	1.1	18
183	Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility. <i>PLoS ONE</i> , 2011, 6, e16964.	1.1	42
184	A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. <i>Genes and Immunity</i> , 2010, 11, 660-664.	2.2	25
185	Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. <i>Nature Genetics</i> , 2010, 42, 469-470.	9.4	23
186	A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e13454.	1.1	55
187	A Transcription Factor Map as Revealed by a Genome-Wide Gene Expression Analysis of Whole-Blood mRNA Transcriptome in Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e14176.	1.1	51
188	The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. <i>Human Molecular Genetics</i> , 2010, 19, 2134-2143.	1.4	128
189	The Audio Recorded Cognitive Screen (ARCS) in patients with multiple sclerosis: a practical tool for multiple sclerosis clinics. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1126-1133.	1.4	24
190	MicroRNAs miR-17 and miR-20a Inhibit T Cell Activation Genes and Are Under-Expressed in MS Whole Blood. <i>PLoS ONE</i> , 2010, 5, e12132.	1.1	225
191	22. Enterovirus meningitis in a patient treated with Natalizumab. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1531-1532.	0.8	0